181 related articles for article (PubMed ID: 31991109)
1. Targeting SOX2 Protein with Peptide Aptamers for Therapeutic Gains against Esophageal Squamous Cell Carcinoma.
Liu K; Xie F; Zhao T; Zhang R; Gao A; Chen Y; Li H; Zhang S; Xiao Z; Li J; Hong X; Shang L; Huang W; Wang J; El-Rifai W; Zaika A; Chen X; Que J; Lan X
Mol Ther; 2020 Mar; 28(3):901-913. PubMed ID: 31991109
[TBL] [Abstract][Full Text] [Related]
2. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
[TBL] [Abstract][Full Text] [Related]
3. Chlorogenic acid inhibits esophageal squamous cell carcinoma growth in vitro and in vivo by downregulating the expression of BMI1 and SOX2.
Zhan Y; Li R; Feng C; Li X; Huang S; Wang L; Liu Z; Jiang J; Han Y
Biomed Pharmacother; 2020 Jan; 121():109602. PubMed ID: 31707349
[TBL] [Abstract][Full Text] [Related]
4. GSK3β-driven SOX2 overexpression is a targetable vulnerability in esophageal squamous cell carcinoma.
Kang L; Liu Y; He J; Wang Y; Xue M; Wu X; Wang Z; Zhang Y; Chu M; Li J; Wei W; Li J; Li E; Liao L; Xiao J; Zhang R; Xu L; Wong J
Oncogene; 2023 Jul; 42(30):2297-2314. PubMed ID: 37349645
[TBL] [Abstract][Full Text] [Related]
5. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
[TBL] [Abstract][Full Text] [Related]
6. Self-assembled RNA nanocarrier-mediated chemotherapy combined with molecular targeting in the treatment of esophageal squamous cell carcinoma.
Li X; Zhang L; Guo X; Xie F; Shen C; Jun Y; Luo C; Liu L; Yu X; Zhang Z; Wang Q; Gao Y; Xu K
J Nanobiotechnology; 2021 Nov; 19(1):388. PubMed ID: 34823537
[TBL] [Abstract][Full Text] [Related]
7. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Gen Y; Yasui K; Nishikawa T; Yoshikawa T
Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
[TBL] [Abstract][Full Text] [Related]
8. Sox2 induces tumorigenesis and angiogenesis of early-stage esophageal squamous cell carcinoma through secretion of Suprabasin.
Takahashi K; Asano N; Imatani A; Kondo Y; Saito M; Takeuchi A; Jin X; Saito M; Hatta W; Asanuma K; Uno K; Koike T; Masamune A
Carcinogenesis; 2020 Nov; 41(11):1543-1552. PubMed ID: 32055838
[TBL] [Abstract][Full Text] [Related]
9. Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.
Zhang L; Niu X; Bi Y; Cui H; Li H; Cheng X
Technol Cancer Res Treat; 2020; 19():1533033820948060. PubMed ID: 32924793
[TBL] [Abstract][Full Text] [Related]
10. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
Chu J; Niu X; Chang J; Shao M; Peng L; Xi Y; Lin A; Wang C; Cui Q; Luo Y; Fan W; Chen Y; Sun Y; Guo W; Tan W; Lin D; Wu C
Theranostics; 2020; 10(8):3488-3502. PubMed ID: 32206103
[No Abstract] [Full Text] [Related]
11. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
12. Pristimerin targeting NF-κB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells.
Tu Y; Tan F; Zhou J; Pan J
Cell Biochem Funct; 2018 Jun; 36(4):228-240. PubMed ID: 29781107
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
[TBL] [Abstract][Full Text] [Related]
14. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.
Jing C; Li X; Zhou M; Zhang S; Lai Q; Liu D; Ye B; Li L; Wu Y; Li H; Yue K; Chen P; Yao X; Wu Y; Duan Y; Wang X
Theranostics; 2021; 11(12):5847-5862. PubMed ID: 33897885
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-429 inhibits the proliferation and migration of esophageal squamous cell carcinoma cells by targeting RAB23 through the NF-κB pathway.
Wang Y; Yu XJ; Zhou W; Chu YX
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1202-1210. PubMed ID: 32096149
[TBL] [Abstract][Full Text] [Related]
16. Pseudolaric Acid B Inhibits Proliferation, Invasion, and Angiogenesis in Esophageal Squamous Cell Carcinoma Through Regulating CD147.
Yin Z; Cai H; Wang Z; Jiang Y
Drug Des Devel Ther; 2020; 14():4561-4573. PubMed ID: 33149553
[TBL] [Abstract][Full Text] [Related]
17. Activation of histamine H
He GH; Ding JQ; Zhang X; Xu WM; Lin XQ; Huang MJ; Feng J; Wang P; Cai WK
J Mol Med (Berl); 2018 Sep; 96(9):951-964. PubMed ID: 30058054
[TBL] [Abstract][Full Text] [Related]
18. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4.
Yang C; Shen S; Zheng X; Ye K; Ge H; Sun Y; Lu Y
FASEB J; 2020 May; 34(5):6055-6069. PubMed ID: 32239565
[TBL] [Abstract][Full Text] [Related]
20. HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway.
Wang H; Yang X; Guo Y; Shui L; Li S; Bai Y; Liu Y; Zeng M; Xia J
J Exp Clin Cancer Res; 2019 Jul; 38(1):324. PubMed ID: 31331361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
